share_log

Brookline Capital Reiterates Buy on Adial Pharmaceuticals, Maintains $6 Price Target

Brookline Capital Reiterates Buy on Adial Pharmaceuticals, Maintains $6 Price Target

Brookline Capital重申买入Adial Pharmicals,维持6美元的目标股价
Benzinga ·  2023/07/12 05:59

Brookline Capital analyst Kumaraguru Raja reiterates Adial Pharmaceuticals (NASDAQ:ADIL) with a Buy and maintains $6 price target.

Brookline Capital分析师Kumaraguru Raja重申了Adial Pharmicals(纳斯达克股票代码:ADIL)的买入,并维持6美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发